Advertisement
Advertisement

RCUS

RCUS logo

Arcus Biosciences, Inc.

10.74
USD
+0.3
+2.78%
Feb 21, 16:00 UTC -5
Closed
exchange

After-Market

11.255

+0.52
+4.80%

Arcus Biosciences, Inc. Profile

About

Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.

Info & Links

CEO

Terry Rosen

Headquarters

3928 Point Eden Way
Hayward, CA 94545, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.arcusbio.com

Auditor

Ernst & Young LLP

Share holders

37

Employees

577

Arcus Biosciences, Inc. Statistics

Valuation Measures

Market Capitalization2

1.03B

Enterprise Value

875.96M

Enterprise Value/EBITDA(ttm)

-2.63

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

3.74

Price to Book(mrq)

1.74

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-102.66%

Profit Margin(ttm)

-173.54%

Return on Equity(ttm)

-45.59%

Return on Invested Capital(ttm)

-47.78%

Return on Assets(ttm)

-22.38%

Income Statement

Revenue(ttm)

263.00M

Revenue Per Share(ttm)

2.87

Gross Profit(ttm)

263.00M

EBITDA(ttm)3

-333.00M

Net Income Available to Common(ttm)

-270.00M

Diluted EPS(ttm)

-3.15

Share Statistics

Beta (5Y Monthly)

0.84

52-Week Change

-34.55%

S&P 500 52-Week Change

18.16%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

91.51M

Dividend Yield

0.00%

Float4

80.26M

% Held by Insiders

12.30%

% Held by Institutions

92.89%

Balance Sheet

Total Cash(mrq)

1.09B

Total Cash Per Share(mrq)

11.90

Total Debt(mrq)

47.00M

Total Debt/Equity(mrq)

8.32%

Current Ratio(mrq)

5.24%

Quick Ratio(mrq)

5.24%

Book Value Per Share(mrq)

6.17

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.77

Free Cash Flow(ytd)

-75.00M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement